|
2.6 Etiologie - Environnement
|
|
|
|
|
|
|
|
|
In
the lawsuit, filed in federal court in California, Monsanto and groups
representing corn, soy and wheat farmers reject that glyphosate causes
cancer. They say the state’s requirement for warnings would force
sellers of products containing the chemical to spread false information.
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
|
|
|
|
|
“Ironically, the term ‘personalised therapy’ can mean something different to everyone,” says Fielding.
|
|
|
|
|
|
|
|
|
|
|
|
|
If
studies show that FGF signaling pathway inhibitors extend survival in
men with androgen-independent metastatic prostate cancer that is
dependent on FGF signaling, the long-term strategy might be to
incorporate FGF inhibitors as part of first-line therapy for metastatic
disease instead of waiting for androgen resistance to develop.
|
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
|
|
|
|
|
For
those stakeholders involved with clinical trials in Europe, the new
Clinical Trial Regulation to be introduced in 2019 will have a dramatic
impact. The aim of the change in regulation is to increase the
efficiency of all trials in Europe, as well as promoting research while
avoiding the duplication of clinical trials.
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
|
|
|
|
|
In
the randomized, placebo-controlled clinical trial, investigators at MD
Anderson will assess the effect of giving SER-401 to patients with
advanced metastatic melanoma who are being treated with an anti-PD-1
checkpoint inhibitor. SER-401 is a preclinical, orally-administered
cocktail of live bacteria.
|
|
|
|
|
|
|
|
|
|
|
|
|
Seres
Chief Executive Roger Pomerantz told Reuters the aim was to start the
randomized, placebo-controlled clinical trial in metastatic melanoma in
2018, evaluating the impact of giving a newly developed Seres microbiome
drug alongside a PD-1 therapy.
|
|
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
|
|
|
|
|
The
company has developed a way to attach to these cells drugs that can
boost immune attack of tumors. These “deep-primed” T cells carry the
immunomodulating drugs to the tumors, where they prompt an immune
response that’s local and targeted to the tumor, rather than one that
happens throughout the body, says Bart Henderson, CEO and co-founder of
Torque.
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
|
|
|
|
At
the American Society of Clinical Oncology’s (ASCO) annual meeting in
June, Loxo reported that 78 percent of the 55 total patients in three
separate clinical trials of larotrectinib responded to treatment,
meaning their tumors at least partially shrunk.
|
|
|
|
|
|
|
|
|
|
|
|
|
Over
the next few years, the deal could result in Loxo receiving a total of
$1 billion. But Loxo shares are down 5% in pre-market trading as
investors balance these payments with Loxo deciding to give up full U.S.
rights to sales from its lead medicine. (The company's shares are up
170% this year.)
|
|
|
|
|
|
|
|
|
|
|
|
|
Loxo's near-term acquisition prospects may have been dampened slightly. But its long-term potential is just as bright.
|
|
|
|
|
|
|
|
|
|
|
|
|
The
deal, which includes Loxo’s follow-up drug LOXO-195, gives Bayer entry
into the fledgling field of drugs that attack cancer based on genetics
rather than the organ where the disease originates.
|
|
|
|
|
|
|
|
|
|
|
|
|
Loxo
Oncology will lead global development activities and United States
(U.S.) regulatory activities. Bayer will lead ex-U.S. regulatory
activities, and worldwide commercial activities.
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
|
|
|
|
Odonate
plans to start enrolling for a Phase III study in metastatic breast
cancer during the fourth quarter of 2017, and have data by 2020.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
|
|
|
|
The
European Medicines Agency (EMA) has published an action plan to improve
the product information (PI) for EU medicines, an information package
for patients and healthcare professionals that accompanies every single
medicine authorised in the EU and explains how it should be used and
prescribed.
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
|
|
|
|
The
FDA approval is based on data from the Phase III MONARCH 2 trial, which
met the study’s primary endpoint of PFS. The trial included 669 women
with HR+, HER2- advanced breast cancer.
|
|
|
|
|
|
|
5.7.1 SABCS-communiqués
|
|
|
|
|
|
|
|
|
Results
from the Phase III MONALEESA-7 trial in premenopausal women with
hormone-receptor positive, human epidermal growth factor receptor-2
negative (HR+/HER2-) advanced or metastatic breast cancer will be
presented for the first time in a late-breaker oral presentation.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
|
|
|
|
The
Australian government recently announced a A$100 million dollar medical
research fund committed to doubling the survival rates and improving
the quality of life of patients with brain cancer over the next ten
years.
|
|
|
|
|
|
|
|
|
|
|
|
|
The
July data release isn’t the culmination of the project. In fact, the
data collecting will end only when the last volunteer has succumbed to
dementia, cancer, or another cause of death.
|
|
|
|
|
|